Single-atom catalysts-based catalytic ROS clearance for efficient psoriasis treatment and relapse prevention via restoring ESR1

Xiangyu Lu, Le Kuai, Fang Huang, Jingsi Jiang, Jiankun Song, Yiqiong Liu, Si Chen, Lijie Mao, Wei Peng, Ying Luo, Yongyong Li, Haiqing Dong (), Bin Li () and Jianlin Shi ()
Additional contact information
Xiangyu Lu: School of Medicine, Tongji University
Le Kuai: Shanghai University of Traditional Chinese Medicine
Fang Huang: School of Medicine, Tongji University
Jingsi Jiang: Tongji University
Jiankun Song: Tongji University
Yiqiong Liu: Tongji University
Si Chen: School of Medicine, Tongji University
Lijie Mao: School of Medicine, Tongji University
Wei Peng: Tongji University
Ying Luo: Shanghai University of Traditional Chinese Medicine
Yongyong Li: Tongji University
Haiqing Dong: Tongji University
Bin Li: Shanghai Academy of Traditional Chinese Medicine
Jianlin Shi: School of Medicine, Tongji University

Nature Communications, 2023, vol. 14, issue 1, 1-15

Abstract: Abstract Psoriasis is a common inflammatory disease of especially high recurrence rate (90%) which is suffered by approximately 3% of the world population. The overexpression of reactive oxygen species (ROS) plays a critical role in psoriasis progress. Here we show that biomimetic iron single-atom catalysts (FeN4O2-SACs) with broad-spectrum ROS scavenging capability can be used for psoriasis treatment and relapse prevention via related gene restoration. FeN4O2-SACs demonstrate attractive multiple enzyme-mimicking activities based on atomically dispersed Fe active structures, which are analogous to those of natural antioxidant enzymes, iron superoxide dismutase, human erythrocyte catalase, and ascorbate peroxidase. Further, in vitro and in vivo experiments show that FeN4O2-SACs can effectively ameliorate psoriasis-like symptoms and prevent the relapse with augmented efficacy compared with the clinical drug calcipotriol. Mechanistically, estrogen receptor 1 (ESR1) is identified as the core protein upregulated in psoriasis treatment through RNA sequencing and bioinformatic analysis. Together, this study provides a proof of concept of psoriasis catalytic therapy (PCT) and multienzyme-inspired bionics (MIB).

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41467-023-42477-y Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-42477-y

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-42477-y

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().